Pfizer: shares jump on early positive Covid-19 vaccine data
(CercleFinance.com) - Pfizer shares jumped over 4% on Wednesday after the US drugmaker said early results from an ongoing phase 1/2 study of its experimental Covid-19 vaccine candidate showed "positive" results.
The company and its German partner BioNTech said they are "encouraged" by preliminary clinical data around BNT162b1, one of four compounds they are evaluating clinically.
At day 28 - seven days after receiving a second dose of the mRNA-based vaccine - all 45 subjects who received the candidate had significantly elevated IgG antibodies, they said.
If ongoing studies prove to be successful and the vaccine candidate receives regulatory approval, Pfizer and BioNTech plan to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The company and its German partner BioNTech said they are "encouraged" by preliminary clinical data around BNT162b1, one of four compounds they are evaluating clinically.
At day 28 - seven days after receiving a second dose of the mRNA-based vaccine - all 45 subjects who received the candidate had significantly elevated IgG antibodies, they said.
If ongoing studies prove to be successful and the vaccine candidate receives regulatory approval, Pfizer and BioNTech plan to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.